93213-75-3

Usage

Uses

Used in Pharmaceutical Industry:
2-(BroMoMethyl)-3-nitrobenzonitrile is used as a starting material for the synthesis of pharmaceutical compounds due to its versatile chemical structure and the presence of a nitro group.
Used in Agrochemical Industry:
2-(BroMoMethyl)-3-nitrobenzonitrile is used as a starting material for the synthesis of agrochemical compounds, contributing to the development of new pesticides and other agricultural products.
Used in Dye and Pigment Production:
2-(BroMoMethyl)-3-nitrobenzonitrile is used as an intermediate in the production of dyes and pigments, enabling the creation of a wide range of colors and properties for various applications.
Used in Specialty Chemicals Production:
2-(BroMoMethyl)-3-nitrobenzonitrile is used as an intermediate in the production of specialty chemicals, such as those used in coatings, plastics, and other industrial applications.
Safety Precautions:
2-(BroMoMethyl)-3-nitrobenzonitrile is considered to be harmful if swallowed, inhaled, or absorbed through the skin. Proper safety precautions should be taken when handling this chemical compound to minimize potential health risks.

Upstream product

• 71516-35-3 2-methyl-3-nitrobenzonitrile 
• 55289-35-5 2-bromo-6-nitrotoluene 

Downstream Products

• 1352609-65-4 3-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methylamino)-2-((dimethylamino)methyl)benzonitrile 
• 1352609-68-7 3-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methylamino)-2-(pyrrolidin-1-ylmethyl)benzonitrile 
• 1352609-71-2 3-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methylamino)-2-(morpholinomethyl)benzonitrile 
• 1352610-56-0 3-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methylamino)-2-((dimethylamino)methyl)benzonitrile hydrochloride 
• 1352610-14-0 3-amino-2-(morpholinomethyl)benzonitrile 
• 1352610-08-2 3-amino-2-(pyrrolidin-1-ylmethyl)benzonitrile 
• 1352610-02-6 3-amino-2-((dimethylamino)methyl)benzonitrile 
• 1352610-03-7 2-((dimethylamino)methyl)-3-nitrobenzonitrile 
• 1352610-09-3 3-nitro-2-(pyrrolidin-1-ylmethyl)benzonitrile 
• 1352610-15-1 2-(morpholinomethyl)-3-nitrobenzonitrile 

Relevant academic research and scientific papers

4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type i receptor kinase

A series of 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2- yl)imidazoles and -pyrazoles 14a-c, 15a-c, 16a, 16b, 19a-d, 21a, and 21b has been synthesized and evaluated for their ALK5 inhibitory activity in an enzyme assay and in a cell-based luciferase reporter assay. Among them, the pyrazole derivative 21b inhibited ALK5 phosphorylation with an IC50 value of 0.018 μM and showed 95% inhibition at 0.03 μM in a luciferase reporter assay using HaCaT cells permanently transfected with p3TP-luc reporter construct. The 21b showed a high selectivity index of 284 against p38α MAP kinase. The binding pose of 21b generated by docking analysis reveals that it fits well into the ATP binding cavity of ALK5 by forming several hydrogen bond interactions.

Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin- 2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent

A series of 2-substituted-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6- methylpyridin-2-yl)imidazoles was synthesized and evaluated to optimize a prototype inhibitor of TGF-β type I receptor kinase (ALK5), 6. Combination of replacement of a quinoxalin-6-yl moiety of 6 with a [1,2,4]triazolo[1,5-a] pyridin-6-yl moiety, insertion of a methyleneamino linker, and a o-F substituent in the phenyl ring markedly increased ALK5 inhibitory activity, kinase selectivity, and oral bioavailability. The 12b (EW-7197) inhibited ALK5 with IC50 value of 0.013 μM in a kinase assay and with IC50 values of 0.0165 and 0.0121 μM in HaCaT (3TP-luc) stable cells and 4T1 (3TP-luc) stable cells, respectively, in a luciferase assay. Selectivity profiling of 12b using a panel of 320 protein kinases revealed that it is a highly selective ALK5/ALK4 inhibitor. Pharmacokinetic study with 12b·HCl in rats showed an oral bioavailability of 51% with high systemic exposure (AUC) of 1426 ng × h/mL and maximum plasma concentration (Cmax) of 1620 ng/mL. Rational optimization of 6 has led to the identification of a highly potent, selective, and orally bioavailable ALK5 inhibitor 12b.